Breaking News Instant updates and real-time market news.

NK

NantKwest

$6.48

-0.11 (-1.67%)

11:04
07/31/17
07/31
11:04
07/31/17
11:04

NantKwest announces durable complete responses in Phase I aNK cell trial

NantKwest announced the final results of a phase I clinical trial of the company's aNK cell therapy platform in relapsed hematological malignancies. The data, published in the journal Oncotarget, demonstrated continuing evidence of safety and efficacy, with an overall response rate of 42% and no evidence of grade 3 or 4 adverse events from the infusions. Of note 2 out of the 12 patients in the safety study with relapsed Hodgkin's Lymphoma and Multiple Myeloma, demonstrated durable complete response with single agent aNK therapy, and remain free of disease to date, 10 years and 2 years respectively. Chairman and CEO Patrick Soon-Shiong said, "Consistent with previous studies, Dr. Keating's clinical trial results, reporting a 42% overall response rate, provide additional clinical validation of the unique potential to deliver long-term remissions with limited toxicity using the company's novel NK cell therapy. Our aNK cell therapy is currently in an ongoing Phase II clinical study in Merkel cell carcinoma and represent a critical, foundational component in the company's recently launched NANT Cancer Vaccine clinical trial program."

NK NantKwest
$6.48

-0.11 (-1.67%)

03/24/17
ADAM
03/24/17
NO CHANGE
Target $7
ADAM
Buy
NantKwest price target lowered to $7 from $18 at Canaccord
Canaccord analyst Arinda Lee lowered her price target on NantKwest to $7 from $18 citing the delay of multiple clinical trials that were expected to begin in 2016. The analyst also lowered the probability of success for the company's aNK drug candidate given increasing competition and expected delayed launch by 1-2 years. Lee maintained her Buy rating on NantKwest shares.
05/15/17
SBSH
05/15/17
DOWNGRADE
Target $3
SBSH
Sell
NantKwest downgraded to Sell from Neutral at Citi
Target $3.
05/16/17
SBSH
05/16/17
DOWNGRADE
Target $3
SBSH
Sell
Citi cuts NantKwest to Sell on 'lack of execution'
Citi analyst Joel Beatty last night downgraded NantKwest to Sell from Neutral and lowered his price target for the shares to $3 from $4. The company has a history of "significantly missing" its clinical trial timelines, and this is unlikely to change over the near-term, Beatty tells investors in a research note. The analyst sees more downside risk on NantKwest's "lack of execution."
05/16/17
05/16/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Sell from Neutral at Citi with analyst Andrew Baum saying his concern over Pfizer's "rising risk to high price" Medicare Part D covered oncology drugs, namely Xtandi, Ibrance and Xalkori, has intensified. He also believes "major transaction risk" for Pfizer remains high. 2. MercadoLibre (MELI) downgraded to Neutral from Overweight at JPMorgan with analyst Andre Baggio citing valuation with the stock up 131% year-over-year. 3. Eli Lilly (LLY) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Jami Rubin citing strong year-to-date performance. The analyst maintained a Buy rating and $92 price target citing favorable long-term fundamentals with significant margin expansion. 4. Valero (VLO) downgraded to Neutral from Buy at Goldman Sachs with analyst Neil Mehta citing a more balanced risk/reward following the stock's outperformance. 5. NantKwest (NK) downgraded to Sell from Neutral at Citi with analyst Joel Beatty saying the company has a history of "significantly missing" its clinical trial timelines, and this is unlikely to change over the near-term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

PDCO

Patterson Companies

$34.82

-1.22 (-3.39%)

07:02
11/21/17
11/21
07:02
11/21/17
07:02
Earnings
Patterson Companies reports Q2 adjusted EPS 51c, consensus 54c »

Reports Q2 revenue $1.4B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 28

    Nov

BLRX

BioLineRx

$1.05

0.04 (3.96%)

07:02
11/21/17
11/21
07:02
11/21/17
07:02
Earnings
BioLineRx reports Q3 EPS (7c), consensus (9c) »

The company held $55M in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

SIG

Signet Jewelers

$75.84

-0.74 (-0.97%)

, ADS

Alliance Data

$224.67

0.32 (0.14%)

07:02
11/21/17
11/21
07:02
11/21/17
07:02
Hot Stocks
Signet in advanced talks with interested partners on more credit outsourcing »

On October 23, Signet…

SIG

Signet Jewelers

$75.84

-0.74 (-0.97%)

ADS

Alliance Data

$224.67

0.32 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 30

    Nov

  • 07

    Dec

  • 08

    Dec

  • 14

    Dec

ENSV

Enservco

$0.65

0.0196 (3.11%)

07:02
11/21/17
11/21
07:02
11/21/17
07:02
Hot Stocks
Enservco enters into agreement with bank »

Enservco announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSW

DSW

$22.53

0.38 (1.72%)

07:02
11/21/17
11/21
07:02
11/21/17
07:02
Earnings
DSW sees FY17 adjusted EPS $1.40-$1.45, consensus $1.50 »

FY17 outlook reflects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

DSW

DSW

$22.53

0.38 (1.72%)

07:00
11/21/17
11/21
07:00
11/21/17
07:00
Earnings
DSW reports Q3 adjusted EPS 45, consensus 53c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

SIG

Signet Jewelers

$75.84

-0.74 (-0.97%)

07:00
11/21/17
11/21
07:00
11/21/17
07:00
Earnings
Signet Jewelers lowers FY18 EPS view to $6.10-$6.50 from $7.16-$7.56 »

Consensus $7.02. Lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 07

    Dec

  • 08

    Dec

RXDX

Ignyta

$15.75

0.85 (5.70%)

07:00
11/21/17
11/21
07:00
11/21/17
07:00
Initiation
Ignyta initiated  »

Ignyta initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

LSI

Life Storage

$87.95

-0.73 (-0.82%)

07:00
11/21/17
11/21
07:00
11/21/17
07:00
Upgrade
Life Storage rating change  »

Life Storage upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SC

Santander Consumer

$17.07

0.75 (4.60%)

06:59
11/21/17
11/21
06:59
11/21/17
06:59
Recommendations
Santander Consumer analyst commentary  »

Santander Consumer added…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

06:59
11/21/17
11/21
06:59
11/21/17
06:59
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRIX

IRIDEX

$7.63

-0.09 (-1.17%)

06:59
11/21/17
11/21
06:59
11/21/17
06:59
Conference/Events
IRIDEX management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

SIG

Signet Jewelers

$75.84

-0.74 (-0.97%)

06:58
11/21/17
11/21
06:58
11/21/17
06:58
Earnings
Signet Jewelers now sees FY18 EPS $6.10-$6.50, consensus $7.02 »

Signet CEO Virginia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 07

    Dec

  • 08

    Dec

GDX

Market Vector Gold Miners

$22.54

-0.25 (-1.10%)

06:58
11/21/17
11/21
06:58
11/21/17
06:58
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$121.31

-1.55 (-1.26%)

06:58
11/21/17
11/21
06:58
11/21/17
06:58
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$28.92

-0.88 (-2.95%)

06:57
11/21/17
11/21
06:57
11/21/17
06:57
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIG

Signet Jewelers

$75.84

-0.74 (-0.97%)

06:57
11/21/17
11/21
06:57
11/21/17
06:57
Earnings
Signet Jewelers reports Q3 EPS with items (20c), consensus 10c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 07

    Dec

  • 08

    Dec

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$14.70

-0.82 (-5.28%)

06:57
11/21/17
11/21
06:57
11/21/17
06:57
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZN

Horizon Global

$14.38

0.49 (3.53%)

06:57
11/21/17
11/21
06:57
11/21/17
06:57
Conference/Events
Horizon Global management to meet with Roth Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

DUST

Direxion Daily Gold Miners Bear 3X ETF

$27.02

0.93 (3.56%)

06:56
11/21/17
11/21
06:56
11/21/17
06:56
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HK

Halcon Resources

$7.12

0.08 (1.14%)

06:56
11/21/17
11/21
06:56
11/21/17
06:56
Conference/Events
Halcon Resources management to meet with Imperial Capital »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 15

    May

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$65.13

3.43 (5.56%)

06:56
11/21/17
11/21
06:56
11/21/17
06:56
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBIN

Merchants Bancorp

$17.68

0.05 (0.28%)

06:55
11/21/17
11/21
06:55
11/21/17
06:55
Initiation
Merchants Bancorp initiated  »

Merchants Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBIN

Merchants Bancorp

$17.68

0.05 (0.28%)

06:55
11/21/17
11/21
06:55
11/21/17
06:55
Initiation
Merchants Bancorp initiated  »

Merchants Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VXX

iPath S&P 500 VIX Short-Term Futures

$33.36

-1.09 (-3.16%)

06:55
11/21/17
11/21
06:55
11/21/17
06:55
Technical Analysis
iPath S&P 500 VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.